Endonovo Therapeutics (ENDV) Stock Statistics & Valuation Metrics

Endonovo Therapeutics has a market cap or net worth of $180.76K. The enterprise value is $6.93M.

Endonovo Therapeutics has 1,807,556,300 shares outstanding. The number of shares has decreased by -2.65% in one year.

Endonovo Therapeutics’s return on equity (ROE) is 0.08 and return on invested capital (ROIC) is 4.32%.

The current PE Ratio of Endonovo Therapeutics is ―. Endonovo Therapeutics’s PEG ratio is 0.00083.

In the last 12 months, Endonovo Therapeutics had revenue of 0.00 and earned -2.18M in profits. Earnings per share was >-0.01.

In the last 12 months, operating cash flow was 100.49K and capital expenditures -8.00, giving a free cash flow of 100.48K billion.

Endonovo Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Endonovo Therapeutics upcoming earnings date is Nov 18, 2024, During Market Hours (Confirmed).

Endonovo Therapeutics as a current ratio of <0.01, with Debt / Equity ratio of -24.78%

In the past 12 months, Endonovo Therapeutics has paid 0.00 in taxes.

Endonovo Therapeutics EV to EBITDA ratio is -7.43, with an EV/FCF ratio of -163.38.

Endonovo Therapeutics has $3.00 in cash and marketable securities with $6.87M in debt, giving a net cash position of -$6.87M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Endonovo Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―